GnRH antagonist is able to rapidly bind GnRH receptors and avoid inhibitory effects on the pituitary gland, while the amount of Gn applied during the ovulation induction cycle is relatively low, which may protect the ovaries comparatively and may also reduce the risk of recurrence of estrogen-sensitive cancers to some extent. The gene discussed is GNRH1; the disease is cancer.